Amarin Corporation is an Irish-American biopharmaceutical company that develops and markets medicines to treat cardiovascular disease.

According to the law firm press release, the Complaint charges that Defendants misrepresented the prospects for Food and Drug Administration (“FDA”) approval of Amarin’s Vascepa drug for the ANCHOR indication and failed to disclose that the FDA had informed Amarin that there was a lack of prospective, controlled clinical trial data demonstrating that pharmaceutical reduction of triglycerides significantly reduces residual cardiovascular risk.

On July 29, 2014, the Court issued an Order consolidating cases, appointing lead Plaintiff, and also approving lead Counsel. Lead Plaintiff filed a consolidated and amended Complaint on September 19.

On April 26, 2016, the Court issued an Order granting Defendants' motion to dismiss without prejudice. Plaintiffs declined to amend their Complaint, thus this case was dismissed with prejudice on May 24. A Notice of Appeal of this decision was filed on May 26. The Court of Appeals issued a Judgment affirming the District Court on May 23, 2017.